Skip to main content

Table 4 Clinical and demographic characteristics of patients who died and those who survived

From: Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa

  Died
(n = 28)
Survived
(n = 63)
P-value
Male sex 24 (85.7) 42 (66.7) 0.06
Age, years* 66.85 (41–84) 65.5 (24–87) 0.12
APACHE II* 14 (5–27) 10.5 (2–28) 0.047
Co-morbidities, n (%):
 Malignancy 6 (21.4) 8 (12.7) 0.35
 Cardiovascular 7 (25) 19 (30.2) 0.8
 Pulmonary 15 (53.6) 18 (28.6) 0.03
 Diabetes Mellitus 3 (10.7) 18 (28.6) 0.1
 Urogenitala 6 (21.4) 8 (12.7) 0.35
 Hepatic 4 (14.3) 4 (6.3) 0.24
 Haematologicalb 4 (14.3) 8 (12.7) 1
 Neurologicalc 2 (7.1) 16 (23.4) 0.05
Charlson* 5 (1–9) 4 (0–10) 0.039
McCabe** 1.8 ± 0.7 1.3 ± 0.6 0.008
Clinical status, n (%)
 Severe sepsis 15 (53.6) 43 (68.3) 0.17
 Shock 2 (7.1) 5 (7.9) 0.89
Patients with CKD at baseline 7 (25) 12 (19) 0.52
Department of hospitalization:
 Medical 12 (42.9) 32 (50.8)  
 Surgical 11 (39.3) 21 (33.3) 0.78
 ICU2 5 (17.9) 10 (15.9)  
Admission diagnosis category:
 Infection 7 (25) 19 (30.2)  
 Other-medical 12 (42.9) 23 (36.5) 0.82
 Other-surgical 9 (32.1) 21 (33.3)  
CMS daily dose (millions IU)** 5.5 ± 2.4 5.4 ± 2.2 0.793
CMS total dose (millions IU)** 114.4 ± 116.5 113.3 ± 91.5 0.68
CMS duration of treatment, days** 20.3 ± 16.5 21.4 ± 16.6 0.88
Combined treatment, n (%) 15 (53.6) 31 (49.2) 0.7
Css (mg/L)** 2,1 ± 1.4 1.4 ± 1,4 0.011
Css > 1.25 (mg/L), n (%) 18 (64.3) 28 (44.4) 0.093
Css/MIC** 4.2 ± 2.7 3.1 ± 3 0.048
AKI at day 7, n (%) 14 (50) 16 (25.4) 0.021
AKI at the EOT, n (%) 20 (71.4) 29 (46) 0.025
Length of hospital stay, (days)** 65.2 ± 33.9 71.5 ± 63.2 0.3
  1. 1 CKD chronic kidney disease, 2 ICU intensive cure unit, 3 CMS colistin methanesulphonate, 4 IU international units, 5 C ss colistin plasma concentration at steady-state, 6 MIC minimal inhibitory concentration, 7 AKI acute kidney injury, 8 EOT end of treatment
  2. *median (range)
  3. **mean ± SD
  4. aAmong urogenital co-morbidities were, renal disease, kidney stones and obstructive uropathy
  5. bAmong haematological co-morbidities were haemopoietic and lymphoreticular malignances
  6. cAmong neurological co-morbidities were Alzheimer’s disease, stroke, miastenia gravis, sclerosis and any kind of dementia